These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 27659891

  • 21. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL.
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [Abstract] [Full Text] [Related]

  • 22. Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial.
    Kario K, Böhm M, Mahfoud F, Townsend RR, Weber MA, Patel M, Tyson CC, Weil J, Agdirlioglu T, Cohen SA, Fahy M, Kandzari DE.
    Circulation; 2018 Oct 09; 138(15):1602-1604. PubMed ID: 30354518
    [No Abstract] [Full Text] [Related]

  • 23. [Second chance for renal artery denervation].
    Chepurnoĭ AG, Shugushev ZK, Maksimkin DA.
    Angiol Sosud Khir; 2021 Oct 09; 27(2):32-40. PubMed ID: 34166342
    [Abstract] [Full Text] [Related]

  • 24. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug.
    Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S.
    Blood Press; 2021 Dec 09; 30(6):327-331. PubMed ID: 34714185
    [No Abstract] [Full Text] [Related]

  • 25. Renal denervation for resistant hypertension and beyond.
    Laffin LJ, Bakris GL.
    Adv Chronic Kidney Dis; 2015 Mar 09; 22(2):133-9. PubMed ID: 25704350
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of renal denervation in the treatment of hypertension: a literature review.
    Shah RT, Wang BX.
    Clin Hypertens; 2022 Apr 15; 28(1):11. PubMed ID: 35422052
    [Abstract] [Full Text] [Related]

  • 27. [Endovascular renal denervation for drug-refractory hypertension : RADIANCE-HTN TRIO].
    Dörr O, Hamm C, Nitschmann S.
    Internist (Berl); 2022 Jan 15; 63(1):129-132. PubMed ID: 34985564
    [No Abstract] [Full Text] [Related]

  • 28. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M.
    J Am Soc Hypertens; 2014 Aug 15; 8(8):593-8. PubMed ID: 25151320
    [Abstract] [Full Text] [Related]

  • 29. Overview of the 2023 FDA Circulatory System Devices Advisory Panel Meeting on the Symplicity Spyral Renal Denervation System.
    Chitturi KR, Haberman D, Wermers JP, Waksman R.
    Am Heart J; 2024 Mar 15; 269():108-117. PubMed ID: 38128897
    [Abstract] [Full Text] [Related]

  • 30. Renal denervation - can we press the "ON" button again?
    Kądziela J, Warchoł-Celińska E, Prejbisz A, Januszewicz A, Witkowski A, Tsioufis K.
    Postepy Kardiol Interwencyjnej; 2018 Mar 15; 14(4):321-327. PubMed ID: 30603021
    [Abstract] [Full Text] [Related]

  • 31. Renal denervation for treatment-resistant hypertension.
    Mafeld S, Vasdev N, Haslam P.
    Ther Adv Cardiovasc Dis; 2012 Dec 15; 6(6):245-58. PubMed ID: 23132232
    [Abstract] [Full Text] [Related]

  • 32. Resistant Hypertension and Renal Nerve Denervation.
    Denker MG, Cohen DL.
    Methodist Debakey Cardiovasc J; 2015 Dec 15; 11(4):240-4. PubMed ID: 27057294
    [Abstract] [Full Text] [Related]

  • 33. Renal denervation in the treatment of resistant arterial hypertension.
    Lambert T, Schützenberger W, Steinwender C.
    Wien Med Wochenschr; 2014 Dec 15; 164(23-24):515-8. PubMed ID: 25394989
    [Abstract] [Full Text] [Related]

  • 34. Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot.
    Snyder EM, Sprissler R, Olson TP.
    Lancet; 2022 Aug 13; 400(10351):491-492. PubMed ID: 35964607
    [No Abstract] [Full Text] [Related]

  • 35. Renal denervation: What happened, and why?
    Shishehbor MH, Hammad TA, Thomas G.
    Cleve Clin J Med; 2017 Sep 13; 84(9):681-686. PubMed ID: 28885911
    [Abstract] [Full Text] [Related]

  • 36. Renal denervation for resistant hypertension: closing in on potential confounders.
    Schlaich MP, Schultz C, Shetty S.
    J Hypertens; 2016 Aug 13; 34(8):1505-6. PubMed ID: 27356001
    [No Abstract] [Full Text] [Related]

  • 37. Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot - Authors' reply.
    Mahfoud F, Kandzari DE, Weber MA, Fahy M, Böhm M.
    Lancet; 2022 Aug 13; 400(10351):492. PubMed ID: 35964608
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    Symplicity HTN-2 InvestigatorsBaker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road, Central Melbourne, VIC 8008, Australia. murray.esler@bakeridi.edu.au, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M.
    Lancet; 2010 Dec 04; 376(9756):1903-9. PubMed ID: 21093036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.